Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Comparable Incidence Rates of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Adult Donors Undergoing Bone Marrow Collection Versus Peripheral Blood Stem Cell Mobilization with Recombinant Human Granulocyte Colony-Stimulating Factor (rHuG-CSF): Results of the Donor Long-Term Follow-up Study By the National Marrow Donor Program (NMDP)

Heather E Stefanski, Stephanie Bo-Subait, Hati Kobusingye, Deborah Mattila, Michelle Kuxhausen, Jennifer Schenfeld, Darcie Sandschafer, Cisio De Oliveira Brandao, Linda J Burns, Bronwen E. Shaw, Michael A. Pulsipher, John P Miller, Steven M Devine

Blood (2022) 140 (Supplement 1): 10862–10864.

https://doi.org/10.1182/blood-2022-159700

Published: 2022

Journal Articles

Ongoing Risk of Unrelated Donors Testing Positive for COVID-19 Following Medical Clearance and Impact on Operations: A Report from the National Marrow Donor Program

Heather E Stefanski, Jennifer Novakovich, Jennifer Newman, Christian Snyder, Meghann Cody, Jason Oakes, Amy Nielson, Jeffery Auletta, John P. Miller, Steven M Devine

Blood (2022) 140 (Supplement 1): 891–892.

https://doi.org/10.1182/blood-2022-168336

Published: 2022

Journal Articles

Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program

Heather E. Stefanski, Jeni Newman, Jennifer Novakovich, Jacklyn Barten, Jason Oakes, Meghann Cody, Huy P Pham, Jeffery Auletta, John P. Miller, Steven Devine

Blood (2021) 138 (Supplement 1): 478.

https://doi.org/10.1182/blood-2021-152952

Published: 2021

Journal Articles

Pain, Symptoms, AEs, and Recovery after Second Unrelated Donor Collection of Marrow/Peripheral Blood Stem Cells Are Similar to Those of the First Donation

David Stroncek, MD, Bronwen E. Shaw, MBChB, PhD MRCP, MRCPath, Brent Logan, PhD, Deidre Marie Kiefer, MPH, Pintip Chitphakdithai, PhD, Galen E. Switzer, PhD, Nirali N Shah, MD, John P. Miller, MD PhD, Dennis L. Confer, MD, Michael A Pulsipher, MD

Blood (2016) 128 (22): 2177.

https://doi.org/10.1182/blood.V128.22.2177.2177

Published: 2016

Journal Articles

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Yi-Bin Chen, MD, Jennifer Le-Rademacher, PhD, Deidre Marie Kiefer, MPH, Mehdi Hamadani, MD, John F. DiPersio, MD PhD, Mark R Litzow, MD, Michael Craig, MD, Mitchell E. Horwitz, MD, Andrew Artz, MD MS, Brian McClune, DO, Edmund K Waller, MD PhD, Hugo F. Fernandez, MD, Hien Kim Duong, MD, Hati Kobusingye, Mandi Proue, MPH, Rebecca J. Drexler, MPH, Mary M. Horowitz, MD MS, John P. Miller, MD PhD, Steven M. Devine, MD

Blood (2015) 126 (23): 389.

https://doi.org/10.1182/blood.V126.23.389.389

Published: 2015

Journal Articles

Baseline Symptoms, Female Sex, and Younger Age Are Correlated with Higher Levels of Peri-Collection Pain, Symptoms, and Persistent Discomfort One Year after Related Donor BM and PBSC Donation: An Analysis of the Related Donor Safety Study (RDSafe)

Michael A. Pulsipher, MD, Brent R. Logan, PhD, Deidre M. Kiefer, MPH, Pintip Chitphakdithai, PhD, Galen E. Switzer, PhD, Marcie L Riches, MD MS, J. Douglas Rizzo, MD, Paolo Anderlini, MD, Susan F. Leitman, James W Varni, PhD, Amy Hays, MPH, RN, Hati Kobusingye, MS, RaeAnne M. Besser, John P. Miller, MD PhD, Rebecca J. Drexler, BS, Roberta J. King, MPH, Mary M. Horowitz, MD MS, Willis H. Navarro, MD, Dennis L. Confer, MD

Blood (2014) 124 (21): 3847.

https://doi.org/10.1182/blood.V124.21.3847.3847

Published: 2014

Journal Articles

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Willis H. Navarro, John E. Levine, John P. Miller, Bronwen E. Shaw, Paul V. O’Donnell, Navneet S. Majhail, Dennis L. Confer

Blood (2014) 123 (23): 3655–3663.

https://doi.org/10.1182/blood-2013-12-542464

Published: 2014

Includes: Supplemental data

Journal Articles

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program

Blood (2013) 121 (1): 197–206.

https://doi.org/10.1182/blood-2012-03-417667

Published: 2013

Includes: Supplemental data

Journal Articles

Significant and Rapid Improvement in Survival After Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT): Analysis of National Marrow Donor Program (NMDP) Facilitated Transplants From 2000 to 2009

Blood (2012) 120 (21): 234.

https://doi.org/10.1182/blood.V120.21.234.234

Published: 2012

Journal Articles

Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34 + cell dose

Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Susan F. Leitman, Paolo Anderlini, John P. Klein, Mary M. Horowitz, John P. Miller, Roberta J. King, Dennis L. Confer

Blood (2009) 114 (13): 2606–2616.

https://doi.org/10.1182/blood-2009-03-208355

Published: 2009

Includes: Supplemental data

Journal Articles

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program

Michael A. Pulsipher, Pintip Chitphakdithai, John P. Miller, Brent R. Logan, Roberta J. King, J. Douglas Rizzo, Susan F. Leitman, Paolo Anderlini, Michael D. Haagenson, Seira Kurian, John P. Klein, Mary M. Horowitz, Dennis L. Confer

Blood (2009) 113 (15): 3604–3611.

https://doi.org/10.1182/blood-2008-08-175323

Published: 2009

NARROW

Ongoing Risk of Unrelated Donors Testing Positive for COVID-19 Following Medical Clearance and Impact on Operations: A Report from the National Marrow Donor Program

Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program

Pain, Symptoms, AEs, and Recovery after Second Unrelated Donor Collection of Marrow/Peripheral Blood Stem Cells Are Similar to Those of the First Donation

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Baseline Symptoms, Female Sex, and Younger Age Are Correlated with Higher Levels of Peri-Collection Pain, Symptoms, and Persistent Discomfort One Year after Related Donor BM and PBSC Donation: An Analysis of the Related Donor Safety Study (RDSafe)

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program

Significant and Rapid Improvement in Survival After Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT): Analysis of National Marrow Donor Program (NMDP) Facilitated Transplants From 2000 to 2009

Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34 + cell dose

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only